Larvol Delta - GSK-to-acquire-emosfermin-a-phase-IIIready-potential-bestinclass-specialty-medicine-to-treat-and-prevent-progression-of-steatotic-liver-disease-SLD

efimosfermin alfa (BOS-580) - GSK

https://www.businesswire.com/news/home/20250513598541/en/GSK-to-acquire-efimosfermin-a-phase-III-ready-potential-best-in-class-specialty-medicine-to-treat-and-prevent-progression-of-steatotic-liver-disease-SLD

May 14, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next